Recent Updates
Recently added Catalysts
ZLAB Positive Sentiment

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Tuesday, September 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab Limited announced that it will present the first global data from a clinical trial evaluating zocilurtatug pelitecan (Zoci) for extensive-stage small cell lung cancer. This presentation will take place at the ESMO Congress 2026 in Madrid, highlighting the potential of Zoci as a first-line treatment option.

Market Sentiment Analysis

POSITIVE FACTORS

  • First global data from a clinical trial will be presented.
  • Zocilurtatug pelitecan shows promise as a first-line treatment.
  • Presentation at a prestigious event like ESMO Congress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Extensive-Stage Small Cell Lung Cancer

Full Press Release Details

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026, in Madrid. Zoci is a novel, potential first-in-class antibody-drug conjugate (ADC

Frequently Asked Questions

What is zocilurtatug pelitecan?

Zocilurtatug pelitecan (Zoci) is a novel antibody-drug conjugate being evaluated for treating ES-SCLC.

When will the data be presented?

The data will be presented at the ESMO Congress 2026, from October 23-27, 2026.

What type of cancer is being targeted?

The clinical trial focuses on extensive-stage small cell lung cancer (ES-SCLC).

Why is this presentation significant?

It marks the first global data sharing for zocilurtatug as a first-line treatment.

ShareAdd on Google
Tags: ZLAB Zai Lab Zocilurtatug ES-SCLC clinical trial ESMO Congress
Last updated: Sep 29, 2026

Biotech snapshot

Cash runway
$618M liquidity · $21M/mo burn
~28 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Extensive-Stage Small Cell Lung Cancer →

Catalyst track record

+60%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →